[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Nacional Autonoma de Honduras\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,78,106,134,159,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642539","phase-2-furosemide-vs-placebo-in-severe-preeclampsia-postpartum-100642539",false,"NCT07648251","Furosemide vs Placebo in Severe Preeclampsia Postpartum","Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial","FUROPE","Inclusion Criteria:\n\n* Signed informed consent (assent for minors 14-17 years with parental\u002Fguardian consent)\n* Confirmed severe preeclampsia (BP ≥160\u002F110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral\u002Fvisual symptoms)\n* Postpartum (12-24 hours after delivery, vaginal or cesarean)\n* Hemodynamically stable (no vasopressors for ≥6 hours)\n* Preserved diuresis (\\>30 mL\u002Fhour for ≥6 hours)\n* Serum creatinine \\\u003C0.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Current or chronic diuretic use (before or during pregnancy)\n* Known allergy to sulfonamides or furosemide\n* Active febrile illness\n* Known chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Participation in another interventional trial\n* Pregnancy (current - not applicable postpartum, but excludes undiagnosed concurrent pregnancy)","FEMALE","14 Years","49 Years",{"count":21,"type":22},186,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.",[28],"Severe Preeclampsia",[30,31,32,33,34],"Preeclampsia","Furosemide","Postpartum","Hypertension","Length of Stay","NOT_YET_RECRUITING","2026-06-09",{"date":38,"type":39},"2026-06-15","ACTUAL",{"date":38,"type":22},{"date":42,"type":22},"2027-01-15",{"name":44,"class":45},"Universidad Nacional Autonoma de Honduras","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100625093","effect-of-maternal-chocolate-consumption-on-fetal-non-stress-test-nst-reactivity-100625093","NCT07418151","Effect of Maternal Chocolate Consumption on Fetal Non-Stress Test (NST) Reactivity.","Effect of Maternal Consumption of Dark Chocolate on the Reactivity of the Fetal Non-Stress Test (NST): A Single-Blind, Randomized Clinical Trial.","CHOCO-NST","Inclusion Criteria:\n\n* Singleton pregnancy between 36+0 and 41+6 weeks of gestation.\n* Baseline Non-Stress Test (NST) classified as non-reactive after a standard 20-minute recording (absence of ≥2 accelerations of ≥15 beats per minute lasting ≥15 seconds).\n* Intact amniotic membranes and not in active labor (cervical dilation \\\u003C4 cm, with absent or irregular contractions).\n* Ability to provide written, informed consent.\n* Literacy: Ability to read and write (to ensure comprehension of the consent form and study materials).\n* Access to a telephone or electronic device for the 24-hour safety follow-up contact.\n\nExclusion Criteria:\n\n1. Pregnancy-related exclusions:\n\n   * Multiple gestation (twins, triplets, etc.).\n   * Known major fetal malformation.\n   * Diagnosis of severe fetal growth restriction with abnormal umbilical artery Doppler.\n   * Premature rupture of membranes.\n   * Active vaginal bleeding or placenta previa with hemorrhage.\n   * Suspected or confirmed chorioamnionitis.\n2. Maternal medical exclusions:\n\n   * Severe preeclampsia, eclampsia, or HELLP syndrome.\n   * Uncontrolled severe hypertension.\n   * Pregestational diabetes or gestational diabetes requiring insulin or other antihyperglycemic medication.\n   * Capillary blood glucose level \\>140 mg\u002FdL at the time of screening.\n   * Maternal fever ≥38°C or maternal tachycardia \\>120 beats per minute.\n3. Interference with test interpretation:\n\n   * Use of sympathomimetic drugs within 12 hours prior to the study intervention.\n   * Maternal cardiac arrhythmias.\n4. Contraindications to the intervention:\n\n   * Known allergy to cocoa or chocolate.\n   * Severe caffeine intolerance.\n   * Phenylketonuria.\n   * Gastrointestinal conditions that would prevent oral intake (e.g., intractable vomiting, ileus, obstruction).",true,"18 Years",{"count":58,"type":22},190,[60],"NA","This is a single-blind, randomized, parallel-group, superiority clinical trial. The study aims to determine whether a single intake of 30g of dark chocolate (≥80% cocoa) by pregnant women with a non-reactive fetal non-stress test (NST) increases the conversion rate to a reactive NST within 20 minutes, compared to observation with a sugar-free white chocolate placebo. A total of 190 singleton pregnant women at 36-41 weeks gestation with a non-reactive NST will be recruited at the Hospital General San Felipe, Tegucigalpa, Honduras. Participants will be randomly assigned to either the intervention group (dark chocolate) or the control group (placebo). The primary outcome is the proportion of NSTs that become reactive. Secondary outcomes include changes in specific cardiotocographic parameters, total monitoring time, need for additional tests, and maternal satisfaction.",[63],"Fetal Distress",[65,66,67,68],"Chocolate","Theobromine","Non-Stress Test","Cardiotocography","RECRUITING","2026-02-27",{"date":72,"type":39},"2026-03-03",{"date":74,"type":22},"2026-02-15",{"date":76,"type":22},"2026-09-30",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":55,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":104,"locationsCount":105},"100626779","phase-4-analgesic-efficacy-and-obstetric-effects-of-tramadol-paracetamol-and-placebo-in-active-labor-100626779","NCT07440069","Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor","Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor: A Randomized Double-Blind Controlled Trial","TRAMPA","Inclusion Criteria:\n\n* Nulliparous pregnant women\n* Age between 15 and 45 years\n* Singleton pregnancy, term (37-41 weeks gestation)\n* Cephalic presentation\n* Active labor defined as cervical dilation ≥4 cm with regular contractions\n* Signed informed consent\n\nExclusion Criteria:\n\n* Multiple gestation or high-risk pregnancy (preeclampsia, gestational diabetes, etc.)\n* Known allergy or contraindication to tramadol or paracetamol\n* Recent use (less than 6 hours) of any analgesic medication\n* Previous cesarean section or other uterine surgery\n* Active infection or fever at admission\n* Inability to provide informed consent due to mental or communication conditions\n* Non-cephalic presentation\n* Rupture of membranes \\>18 hours without labor\n* Participation in another clinical trial within the last 3 months","15 Years","45 Years",{"count":89,"type":22},300,[91],"PHASE4","This randomized, double-blind, placebo-controlled trial aims to compare the analgesic efficacy and obstetric effects of tramadol (100 mg IV) versus paracetamol (1 g IV) versus placebo (saline solution) in nulliparous women during active labor. The primary outcome is duration of active labor (minutes). Secondary outcomes include duration of expulsive phase, type of delivery, need for oxytocin augmentation, maternal adverse events (nausea, vomiting, somnolence, hypotension), and neonatal outcomes (Apgar scores at 1 and 5 minutes, NICU admission). The study hypothesizes that tramadol significantly reduces active labor duration compared to paracetamol and placebo, without compromising maternal or neonatal safety. A total of 300 nulliparous women (100 per group) will be enrolled at Hospital Escuela, Tegucigalpa, Honduras.",[94],"Labor Pain",[96,97,98,94,99],"Tramadol","Paracetamol","Acetaminophen","Labor Duration","2026-02-24",{"date":70,"type":39},{"date":74,"type":22},{"date":76,"type":22},{"name":44,"class":45},2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":133,"locationsCount":46},"100625875","use-of-lubricant-gel-to-shorten-the-second-stage-of-labor-during-vaginal-delivery-100625875","NCT07428317","Use of Lubricant Gel to Shorten the Second Stage of Labor During Vaginal Delivery","Use of Lubricant Gel to Shorten the Second Stage of Labor During Vaginal Delivery: A Randomized Single-Blind Clinical Trial","OBY-GEL","Inclusion Criteria:\n\n* Signed informed consent form\n* Willingness to comply with study procedures\n* Age between 18 and 40 years\n* Term pregnancy (37-41.6 weeks) with active labor\n* Diagnosis of spontaneous labor and planned vaginal delivery\n* Fetus in cephalic presentation\n* Agreement to comply with lifestyle restrictions during the study\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Previous cesarean section\n* High-risk pregnancy (preeclampsia, uncontrolled gestational diabetes, etc.)\n* Presence of fever or active infection\n* Contraindication for vaginal delivery\n* Refusal to sign informed consent\n* Premature rupture of membranes \\>18 hours without labor\n* Known allergy to lubricant gel components\n* Participation in another clinical trial in the last 3 months",{"count":115,"type":22},160,[60],"This experimental study aims to evaluate whether the application of obstetric lubricant gel during vaginal delivery can significantly reduce the duration of the second stage of labor, preserve perineal integrity, and decrease the need for episiotomies. The study hypothesis is that lubricant gel facilitates fetal passage through the birth canal by reducing friction, shortening the expulsion phase and reducing maternal-neonatal complications. Two groups will be included: with and without gel application. Follow-up will span from admission of the pregnant woman until immediate postpartum discharge.",[119],"Prolonged Second Stage of Labor",[121,122,123,124,125,126,99,127],"Lubricant Gel","Second Stage of Labor","Perineal Integrity","Episiotomy","Vaginal Delivery","Obstetric Gel","Birth Canal Lubrication","2026-02-16",{"date":130,"type":39},"2026-02-23",{"date":128,"type":39},{"date":76,"type":22},{"name":44,"class":45},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":158,"locationsCount":105},"100623786","umbilical-cord-drainage-to-prevent-postpartum-hemorrhage-100623786","NCT07401160","Umbilical Cord Drainage to Prevent Postpartum Hemorrhage","Relationship Between Umbilical Cord Drainage and Postpartum Hemorrhage: A Randomized Single-Blind Clinical Trial.","CORD-PPH","Inclusion Criteria:\n\n* Pregnant women aged 18-49 years.\n* Singleton pregnancy.\n* Gestational age ≥37 weeks.\n* active labor with cephalic presentation.\n* Planned for vaginal delivery.\n* Capable of providing informed consent.\n\nExclusion Criteria:\n\n* Planned or emergent cesarean section.\n* Instrumental delivery (e.g., forceps, vacuum).\n* Antepartum hemorrhage.\n* Severe anemia (Hemoglobin \\\u003C8 g\u002FdL) or specific hematological disorders (e.g., sickle cell disease, thalassemia, hemophilia, thrombocytopenia \\\u003C100,000\u002FµL).\n* Use of anticoagulant medication.\n* Non-cephalic fetal presentation (e.g., breech, transverse).\n* Refusal to participate or inability to provide informed consent.",{"count":143,"type":22},400,[60],"This study aims to analyze whether there is a significant difference in the occurrence of postpartum hemorrhage between women who underwent umbilical cord drainage and those who did not. Variables such as estimated blood loss volume, drop in hemoglobin levels, and the need for additional maneuvers or treatments to control hemorrhage will be examined. The research will be conducted under a parallel-group clinical trial design at the Hospital Escuela Universitario. Post-birth umbilical cord drainage may contribute to a lower frequency of postpartum hemorrhage compared to not performing it.",[147],"Postpartum Hemorrhage",[149,150,151,152],"Cord Drainage","Third Stage of Labor","Obstetric Hemorrhage","Labor Stage","2026-02-10",{"date":155,"type":39},"2026-02-13",{"date":74,"type":22},{"date":76,"type":22},{"name":44,"class":45},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":87,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":180,"locationsCount":46},"100624570","left-lateral-position-vs-supine-position-to-reduce-active-labor-duration-100624570","NCT07411352","Left Lateral Position vs Supine Position to Reduce Active Labor Duration","Left Lateral Position Versus Supine Position in Reducing the Duration of the Active Phase of Labor: A Randomized, Single-Blind Clinical Trial","DLI-SP","Inclusion Criteria:\n\n* Signed and dated informed consent form.\n* Nulliparous woman.\n* Singleton pregnancy at ≥37 weeks of gestation.\n* Intact amniotic membranes.\n* Cephalic presentation.\n* In the active phase of labor (cervical dilation ≥6 cm).\n* Age ≥18 years.\n* No contraindication for vaginal delivery.\n* Possession of a mobile phone (for potential follow-up contact).\n\nExclusion Criteria:\n\n* Previous uterine surgery.\n* Maternal condition preventing vaginal delivery.\n* Fetal anomaly.\n* Premature rupture of membranes.\n* Multiple pregnancy.\n* Fetal demise.\n* Uterine myomas.\n* Maternal comorbidities (e.g., chronic hypertension, diabetes mellitus type -1\u002F2\u002Fgestational, hypothyroidism).\n* Anemia.\n* Age \\\u003C18 years.\n* Preterm gestation (\\\u003C37 weeks).",{"count":168,"type":22},188,[60],"This randomized clinical trial aims to compare the effect of the left lateral decubitus position versus the supine position on the duration of the active phase of labor in nulliparous women. A total of 188 participants will be randomly assigned to one of two groups. The intervention group will be placed in the left lateral decubitus position, while the control group will remain in the supine position. Both positions will be maintained for 30-minute intervals with 5-minute rest periods, continuing until delivery. The primary outcome is the duration of the active phase of labor. Secondary outcomes include rates of cesarean section, use of oxytocin and analgesics, and maternal and neonatal complications.",[94],[173,174,175,176],"Maternal Position","Left Lateral Position","Active Phase of Labor","Randomized Controlled Trial",{"date":155,"type":39},{"date":74,"type":22},{"date":76,"type":22},{"name":44,"class":45},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":46},"100528733","phase-2-use-of-cinnamomum-verum-for-induction-of-labor-double-blind-randomized-clinical-trial-100528733","NCT06164613","Use of Cinnamomum Verum for Induction of Labor. Double Blind Randomized Clinical Trial","Use of Cinnamomum Verum Extract Versus Placebo for Induction of Labor and Reduction of Physiological Phase 2-3 of Labor. Double-blind Randomized Clinical Trial. CINNALAB TRIAL","CINNALAB","Inclusion Criteria:\n\n1. Delivery of an informed consent form signed and dated by parents or guardian and patient\n2. Declared willingness to comply with all study procedures and availability for the duration of the study.\n3. provision of appropriate consent and assent\n4. Willingness and ability to participate in study procedures\n5. Patients under 18 years of age\n6. Full-term pregnancies (37-41 Weeks of Gestation).\n7. Nulliparity\n8. Have your own cell phone\n9. Know how to read and write\n10. Residing in Tegucigalpa\n11. Be in good general health, as evidenced by your medical history\n12. Ultrasound with amniotic fluid index \\> 5 cm\n13. Non Stress Test Reactive\n14. Ability to take oral medication and be willing to comply with the cinnamon capsule regimen\n\nExclusion Criteria:\n\n1. Current use of antihypertensive or hypoglycemic medications\n2. Presence of non-curable chronic diseases prior to pregnancy or during pregnancy such as hypertension, diabetes, hypothyroidism\n3. Premature rupture of membranes\n4. Infections (urinary tract infection, chorioamnionitis) present at the time of the study (diagnosed with symptoms or leukocytes \\>12,500 or pathological urine examination)\n5. Allergies to cinnamaldehyde or cinnamon, canola oil\n6. Multiple pregnancy\n7. Major fetal malformations\n8. Fetal death\n9. Non-cephalic presentation\n10. Severe oligohydramnios (amniotic fluid index \\\u003C 2 cm)\n11. Having consumed or being consuming cinnamon products 7 days before the start of the study\n12. Febrile illness within 7 days before starting to take cinnamon\n13. Treatment with another investigational drug or other intervention within 7 days prior to the start of the intervention\n14. Current smoker or tobacco use",{"count":190,"type":22},70,[25],"The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated.\n\nCinnamon has been reported for its ethnopharmacological properties in pregnancy, being used to facilitate childbirth, as a lactagogue and for postpartum recovery. In Honduras, its use has been reported to relieve nausea and vomiting during pregnancy, to reduce abdominal pain. , reduction of lower limb edema, to relieve anxiety during labor, as well as a lactagogue without convergent opinions.",[194,195],"Labor Onset and Length Abnormalities","First Birth",[197,198,199],"cinnamon oil, bark","labor onset","nulliparity","2025-11-26",{"date":202,"type":39},"2025-12-04",{"date":204,"type":39},"2023-12-04",{"date":206,"type":22},"2026-12-30",{"name":44,"class":45},""]